CRBP

CorbusD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$18.00

+138.7% vs current

Most likely

Base case

45%

Probability

Target price

$9.00

+19.4% vs current

B-

Bear case

30%

Probability

Target price

$5.00

-33.7% vs current

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Primary-source evidence supports a constructive but still monitoring-style setup: Corbus has credible 2026 catalyst timing and reduced near-term financing pressure, yet forward visibility remains dependent on binary oncology and obesity readouts. Given the negative deterministic prior, only moderate evidence quality, and loose peer set, the thesis is better framed as cautious event-driven optionality than a high-conviction bullish call.

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-29catalystUpdated CRB-701 monotherapy data at ASCO 2026High impact

Corbus said updated Phase 1/2 monotherapy data in HNSCC and cervical cancer will be presented at ASCO 2026, including durability and HNSCC subgroup detail; this is the cleanest near-term efficacy catalyst for the lead oncology asset [#PR-2026-04-07].

2026-06-30catalystRunway appears sufficient to bridge 2026 data eventsHigh impact

The March corporate update tied to the FY2025 reporting cycle said Corbus completed a $75 million public offering in Q4 2025 and extended cash runway into 2028, which lowers immediate financing pressure as 2026 readouts approach, though it does not remove later dilution risk [#PR-2026-03-09] [#10-K-2026-03-09].

2026-07-15catalystPotential CRB-701 registrational-study start after FDA alignmentHigh impact

Management disclosed broad FDA alignment on registrational paths in second-line HNSCC and cervical cancer and said it expects to initiate a registrational HNSCC study in mid-2026, which would materially improve development-path clarity if timelines hold [#PR-2026-04-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology